Efficacy and Safety of Globin Digest as a Functional Beverage for the Treatment of Childhood Obesity

Daisuke Tokuhara^1, , Eri Hayashi², Yuki Cho¹ and Haruo Shintaku¹

¹Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan

²Department of Pediatrics, Izumi Municipal Hospital, Osaka, Japan

Cite this paper:
Daisuke Tokuhara, Eri Hayashi, Yuki Cho and Haruo Shintaku. Efficacy and Safety of Globin Digest as a Functional Beverage for the Treatment of Childhood Obesity. Journal of Food and Nutrition Research. 2017; 5(4):281-284. doi: 10.12691/jfnr-5-4-10

Abstract

Background and aims: Childhood obesity is a serious health concern in many countries in the world. In addition to lifestyle education, functional foods or beverages may be useful for preventing and treating obesity. Here we evaluated the effectiveness and safety of a globin digest (GD) functional beverage for the treatment of childhood obesity. Methods: Twenty-eight obese Japanese children (median age, 12.4 years; range, 6.0–17.3 years; 18 males) were randomly assigned to receive orally either placebo beverage (n = 14) or GD beverage containing 6 mg of the amino acid residue Val-Val-Tyr-Pro (n = 14) within 1 h of eating dinner daily for 3 months. Changes in body weight, body mass index percentile, and percentage overweight were based on Japanese age-, sex-, and height-specific body-weight standards. The prevalence of adverse events was also evaluated. Results: The changes in body weight, body mass index percentile, or percentage overweight were not significantly different between the two groups at 3 months or at 6 months after the start of GD intake. No adverse events were reported in any of the subjects. Conclusions: Although the effectiveness of GD beverages for the treatment of childhood obesity needs further evaluation, the GD beverage used in the present study was safe and had good compliance in obese Japanese children.

Keywords:
globin digest obesity children triglyceride functional beverage

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E.C., Biryukov, S., Abbafati, C., et al, “Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013,” Lancet, 384 (9945). 766-781. Aug 2014.
[2]	Togashi, K., Masuda, H., Rankinen, T., Tanaka, S., Bouchard, C. and Kamiya, H, “A 12-year follow-up study of treated obese children in Japan,” Int J Obes Relat Metab Disord, 26 (6). 770-777. Jun 2002.
[3]	Ogden, C.L., Carroll, M.D., Kit, B.K. and Flegal, K.M, “Prevalence of childhood and adult obesity in the United States, 2011-2012,” JAMA, 311 (8). 806-814. Feb 2014.
[4]	Matsushita, Y., Yoshiike, N., Kaneda, F., Yoshita, K. and Takimoto, H, “Trends in childhood obesity in Japan over the last 25 years from the national nutrition survey,” Obes Res, 12 (2). 205-214. Feb 2004.
[5]	Tominaga, K., Kurata, J.H., Chen, Y.K., Fujimoto, E., Miyagawa, S., Abe, I. and Kusano, Y, “Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey,” Dig Dis Sci, 40 (9). 2002-2009. Sep 1995.
[6]	Schwimmer, J.B., Deutsch, R., Kahen, T., Lavine, J.E., Stanley, C. and Behling, C, “Prevalence of fatty liver in children and adolescents,” Pediatrics, 118 (4). 1388-1393. Oct 2006.
[7]	Wadden, T.A., Volger, S., Sarwer, D.B., Vetter, M.L., Tsai, A.G., Berkowitz, R.I., Kumanyika, S., et al, “A two-year randomized trial of obesity treatment in primary care practice,” N Engl J Med, 365 (21). 1969-1979. Nov 2011.
[8]	Martin, P.D., Dutton, G.R., Rhode, P.C., Horswell, R.L., Ryan, D.H. and Brantley, P.J, “Weight loss maintenance following a primary care intervention for low-income minority women,” Obesity (Silver Spring), 16 (11). 2462-2467. Nov 2008.
[9]	Christian, J.G., Bessesen, D.H., Byers, T.E., Christian, K.K., Goldstein, M.G. and Bock, B.C, “Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight,” Arch Intern Med, 168 (2). 141-146. Jan 2008.
[10]	Ockene, I.S., Hebert, J.R., Ockene, J.K., Saperia, G.M., Stanek, E., Nicolosi, R., Merriam, P.A. and Hurley, T.G, “Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH),” Arch Intern Med, 159 (7). 725-731. Apr 1999.
[11]	Chen, H.C. and Farese, R.V. Jr, “Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice,” Arterioscler Thromb Vasc Biol, 25 (3). 482-486. Mar 2005.
[12]	Kagawa, K., Matsutaka, H., Fukuhama, C., Watanabe, Y. and Fujino, H, “Globin digest, acidic protease hydrolysate, inhibits dietary hypertriglyceridemia and Val-Val-Tyr-Pro, one of its constituents, possesses most superior effect,” Life Sci, 58 (29). 1745-1755. Apr 1996.
[13]	Kagawa, K., Matsutaka, H., Fukuhama, C., Fujino, H. and Okuda, H, “Suppressive effect of globin digest on postprandial hyperlipidemia in male volunteers,” J Nutr, 128 (1). 56-60. Jan 1998.
[14]	Yamamoto, K., Sasakawa, Y., Nakaoka, F., Nakao, M., Nakamura, M., Kominami, A., Abe, M., Fukuhama, C. and Kagawa K, “Effect of globin digest on the liver injury and hepatic gene expression profile in galactosamine-induced liver injury in SD rats,” Life Sci, 88 (15-16). 701-712. Apr 2011.
[15]	Asayama, K., Ozeki, T., Sugihara, S., Ito, K., Okada, T., Tamai, H., Takaya, R., Hanaki, K. and Murata M, “Criteria for medical intervention in obese children: a new definition of 'obesity disease' in Japanese children,” Pediatr Int, 45 (5). 642-646. Oct 2003.
[16]	Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B., Flegal, K., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee, “Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, 119 (3). 480-486. Jan 2009.
[17]	Mokdad, A.H., Ford, E.S., Bowman, B.A., Dietz, W.H., Vinicor, F., Bales, V.S. and Marks, J.S, “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001,” JAMA, 289 (1). 76-79. Jan 2003.
[18]	Luyckx, F.H., Desaive, C., Thiry, A., Dewé, W., Scheen, A.J., Gielen, J.E. and Lefèbvre, P.J, “Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty,” Int J Obes Relat Metab Disord, 22 (3). 222-226. Mar 1998.
[19]	Cho, Y., Tokuhara, D., Morikawa, H., Kuwae, Y., Hayashi, E., Hirose, M., Hamazaki, T., Tanaka, A., Kawamura, T., Kawada, N. and Shintaku, H, “Transient Elastography-Based Liver Profiles in a Hospital-Based Pediatric Population in Japan,” PLoS One, 10 (9). e0137239. Sep 2015.
[20]	Hill, J.O. and Peters, J.C, “Biomarkers and functional foods for obesity and diabetes,” Br J Nutr, 88 (suppl 2). S213-S218. Nov 2002.
[21]	Astrup, A., Breum, L., Toubro, S., Hein, P. and Quaade, F, “The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial,” Int J Obes Relat Metab Disord, 16 (4). 269-277. Apr 1992.
[22]	Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H.P. and Krempf, M, “Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group,” Lancet, 352 (9123). 167-172. Jul 1998.
[23]	Chaput, E., Saladin, R., Silvestre, M. and Edgar, A.D, “Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight,” Biochem Biophys Res Commun, 271 (2). 445-450. May 2000.